Clinical Trial Update: Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Nonvalvular Atrial Fibrillation (NVAF) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing edoxaban to warfarin in patients undergoing cardioversion for nonvalvular atrial fibrillation completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation

Drugs mentioned

• Edoxaban (edoxaban)
• Warfarin (warfarin)

Snippet

Sponsor: Daiichi Sankyo | Conditions: Atrial Fibrillation | Phase 3 | Status: COMPLETED | Results posted: 2019-03-13